Download
s00259-021-05348-6.pdf 1,26MB
WeightNameValue
1000 Titel
  • FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
1000 Autor/in
  1. Kaddu-Mulindwa, Dominic |
  2. Altmann, Bettina |
  3. Held, Gerhard |
  4. Angel, Stephanie |
  5. Stilgenbauer, Stephan |
  6. Thurner, Lorenz |
  7. Bewarder, Moritz |
  8. Schwier, Maren |
  9. Pfreundschuh, Michael |
  10. Löffler, Markus |
  11. Menhart, Karin |
  12. Grosse, Jirka |
  13. Ziepert, Marita |
  14. Herrmann, Ken |
  15. Dührsen, Ulrich |
  16. Hüttmann, Andreas |
  17. Barbato, Francesco |
  18. Poeschel, Viola |
  19. Hellwig, Dirk |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-04-29
1000 Erschienen in
1000 Quellenangabe
  • 48(11):3550-3559
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00259-021-05348-6 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440256/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB).!##!Methods!#!Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. The reference standard to confirm BMI included a positive BMB and/or FDG PET/CT confirmed by targeted biopsy, complementary imaging (CT or magnetic resonance imaging), or concurrent disappearance of focal FDG-avid BM lesions with other lymphoma manifestations during immunochemotherapy.!##!Results!#!Among 930 patients, BMI was detected by BMB in 85 (prevalence 9%) and by FDG PET/CT in 185 (20%) cases, for a total of 221 cases (24%). All 185 PET-positive cases were true positive, and 709 of 745 PET-negative cases were true negative. For BMB and FDG PET/CT, sensitivity was 38% (95% confidence interval [CI]: 32-45%) and 84% (CI: 78-88%), specificity 100% (CI: 99-100%) and 100% (CI: 99-100%), positive predictive value 100% (CI: 96-100%) and 100% (CI: 98-100%), and negative predictive value 84% (CI: 81-86%) and 95% (CI: 93-97%), respectively. In all of the 36 PET-negative cases with confirmed BMI patients had other adverse factors according to IPI that precluded a change of standard treatment. Thus, the BMB would not have influenced the patient management.!##!Conclusion!#!In patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG PET/CT and could therefore be omitted.!##!Trial registration!#!NCT00554164 and NCT01478542.
1000 Sacherschließung
lokal Bone Marrow/diagnostic imaging [MeSH]
lokal Lymphoma
lokal Biopsy [MeSH]
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal FDG PET/CT
lokal Positron Emission Tomography Computed Tomography [MeSH]
lokal Retrospective Studies [MeSH]
lokal Bone marrow biopsy
lokal Hematology
lokal Fluorodeoxyglucose F18 [MeSH]
lokal Lymphoma, Non-Hodgkin/diagnostic imaging [MeSH]
lokal Original Article
lokal Neoplasm Staging [MeSH]
lokal Aggressive B-cell lymphoma
lokal Positron-Emission Tomography [MeSH]
lokal Bone Marrow/pathology [MeSH]
lokal Diagnostic performance
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-8832-252X|https://frl.publisso.de/adhoc/uri/QWx0bWFubiwgQmV0dGluYQ==|https://frl.publisso.de/adhoc/uri/SGVsZCwgR2VyaGFyZA==|https://frl.publisso.de/adhoc/uri/QW5nZWwsIFN0ZXBoYW5pZQ==|https://frl.publisso.de/adhoc/uri/U3RpbGdlbmJhdWVyLCBTdGVwaGFu|https://frl.publisso.de/adhoc/uri/VGh1cm5lciwgTG9yZW56|https://frl.publisso.de/adhoc/uri/QmV3YXJkZXIsIE1vcml0eg==|https://frl.publisso.de/adhoc/uri/U2Nod2llciwgTWFyZW4=|https://frl.publisso.de/adhoc/uri/UGZyZXVuZHNjaHVoLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/TMO2ZmZsZXIsIE1hcmt1cw==|https://frl.publisso.de/adhoc/uri/TWVuaGFydCwgS2FyaW4=|https://frl.publisso.de/adhoc/uri/R3Jvc3NlLCBKaXJrYQ==|https://frl.publisso.de/adhoc/uri/WmllcGVydCwgTWFyaXRh|https://frl.publisso.de/adhoc/uri/SGVycm1hbm4sIEtlbg==|https://frl.publisso.de/adhoc/uri/RMO8aHJzZW4sIFVscmljaA==|https://frl.publisso.de/adhoc/uri/SMO8dHRtYW5uLCBBbmRyZWFz|https://frl.publisso.de/adhoc/uri/QmFyYmF0bywgRnJhbmNlc2Nv|https://frl.publisso.de/adhoc/uri/UG9lc2NoZWwsIFZpb2xh|https://orcid.org/0000-0002-3056-0143
1000 Hinweis
  • DeepGreen-ID: 551d36bc0bf449e9b107281f60a4f25d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451533.rdf
1000 Erstellt am 2023-05-11T13:52:15.637+0200
1000 Erstellt von 322
1000 beschreibt frl:6451533
1000 Zuletzt bearbeitet 2023-10-24T07:25:53.571+0200
1000 Objekt bearb. Tue Oct 24 07:25:53 CEST 2023
1000 Vgl. frl:6451533
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451533 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source